Orthopedic Biologics Supplier Serving Allentown, Pennsylvania

Vendor Review Steps Used by Orthopedic Groups

Orthopedic practices and ambulatory surgery centers in the Northeast generally document a vendor qualification process before adding a biologics line, including confirming distribution status, requesting a certificate of analysis for the specific lot, and having a medical director review the paperwork. Because Wharton's jelly allografts and exosome products are regulated differently, groups often ask vendors to specify which framework applies to each product before purchase.

• Confirm distributor registration status
• Request certificate of analysis by lot
• Route documentation to medical director for review

Logistics for Shipments Into the Northeast

Cryopreserved products ship overnight on dry ice in validated containers and are stored at -80 degrees Celsius before shipment. Practices in Allentown and similar Northeast markets should plan for a staff member to receive and log the shipment, verify the container held temperature in transit, and move product into storage without delay.

Lyophilized formats do not require cold-chain handling, which some surgery centers use to simplify receiving logistics across multiple sites.

NPI Verification and Credentialing Checks

Account setup requires a valid NPI number tied to the ordering physician or practice. Precision Biologics verifies that number against the NPPES registry and confirms the supervising or ordering physician before activating purchasing access. Orthopedic groups should also verify their own standing with the Pennsylvania medical board and confirm documentation requirements with their legal counsel, since Precision Biologics does not advise on intended use or clinical application.

Ongoing Documentation and Support

Once an account is verified, practices can request a certificate of analysis, donor eligibility summary, and lot release record for any product under consideration. Our team is available for physician-level calls focused on product documentation and specifications, not clinical guidance, to help new accounts move through setup and ordering.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.